AUTOLUS
Live / Registered — Registered (as of 13 Jan 2026)
What this means for you
Registered since 13 Jan 2026. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 79420853
- Registration number
- 8097979
- Mark type
- Design + words
- Filed
- 27 Jan 2025
- Published for opposition
- 25 Nov 2025
- Registered
- 13 Jan 2026
- Attorney of record
- Rebecca Liebowitz
Goods and services
- Class 005 — Pharmaceuticals: Medical and veterinary preparations for the treatment of cancer, genetic conditions, immune response disorders, autoimmune disorders, infectious diseases, ophthalmological conditions, hematologic diseases, neurological disorders, respiratory diseases, metabolic diseases and cardiovascular diseases for therapeutic purposes; pharmaceutical preparations for cell therapy; pharmaceutical preparations for gene therapy for the treatment of cancer, genetic conditions, immune response disorders, autoimmune disorders, infectious diseases, ophthalmological conditions, hematologic diseases, neurological disorders, respiratory diseases, metabolic diseases and cardiovascular diseases; pharmaceutical preparations for cancer therapies; pharmaceutical preparations for the treatment of autoimmune diseases; pharmaceutical preparations for treatment of cancer comprising chimeric antigen receptors (CAR) and therapeutic preparations thereof; antibodies for medical purposes; pharmaceutical preparations for genetically modifying human or animal cells for medical purposes, in particular viral vectors; pharmaceutical preparations of blood extracted from humans or animals which have been adapted for therapeutic purposes for the treatment of cancer, genetic conditions, immune response disorders, autoimmune disorders, infectious diseases, ophthalmological conditions, hematologic diseases, neurological disorders, respiratory diseases, metabolic diseases and cardiovascular diseases; pharmaceutical preparations for use in the treatment of cancer; pharmaceutical preparations for use in the treatment of autoimmune diseases; biological preparations for the treatment of cancer; biological preparations for use in the treatment of autoimmune diseases; pharmaceutical and biological preparations for immunotherapy, in particular T cell therapy; vaccines
- Class 040 — Treatment of materials: Custom manufacture of therapeutic drugs, namely cell therapies, preparations to treat autoimmune diseases, cancer therapies and cancer vaccines
- Class 042 — Scientific and technological services: Scientific and technological services and research and design relating thereto, namely, medical research, scientific research, analysis and testing in the field of human and animal cell, gene and cancer therapies, pharmaceutical product development, research and development of new products; industrial analysis and research services in the field of cell, gene and cancer therapies; medical and veterinary research services, in particular in the field of the manipulation of cells within a laboratory or research facility to enable the cells to be used for therapeutic purposes; scientific research in the development of autoimmune diseases and new cancer therapies; scientific research in human and animal cell therapy; scientific research in human and animal gene therapy; scientific research into vaccines, in particular personalised cancer vaccines; scientific research into vectors and preparations for manipulating and adapting human and animal cells; consultancy relating to all the aforesaid services
- Class 044 — Medical, beauty and agricultural services: Medical services; veterinary services; medical services for the extraction of human and animal cells from patients; medical services, namely, manipulation of human and animal cells for therapeutic purposes; medical services, namely, reinsertion of cells into human and animal patients; medical and veterinary services, namely, providing advice and consultancy in the field of medical and veterinary therapies; medical and veterinary services, namely, providing advice and consultancy in the field of autoimmune diseases, cancer therapies and cancer vaccines
Owner
- Autolus Limited, GB
- Autolus Limited, GB
- Autolus Limited, GB
Prosecution history
- 13 Jan 2026 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 13 Jan 2026 — REGISTERED-PRINCIPAL REGISTER
- 25 Nov 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 25 Nov 2025 — PUBLISHED FOR OPPOSITION
- 19 Nov 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 27 Oct 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 27 Oct 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 27 Oct 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 27 Oct 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 12 Jul 2025 — REFUSAL PROCESSED BY IB
- 21 Jun 2025 — NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
- 21 Jun 2025 — REFUSAL PROCESSED BY MPU
- 18 Apr 2025 — NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
- 17 Apr 2025 — NON-FINAL ACTION WRITTEN
- 09 Apr 2025 — ASSIGNED TO EXAMINER